Loading...
Market
Objective response rate in final GALAXIES Lung-201 study results by June 30, 2025?
2
Resolution / Starting Odds
Less than 50% • 25%
50% - 60% • 25%
60% - 70% • 25%
More than 70% • 25%
Final study results published in medical journals or presented at conferences
Story
iTeos and GSK Show Promising Anti-TIGIT Results in Lung Cancer Study at ESMO 2024
Sep 14, 2024, 06:32 AM
iTeos Therapeutics and GSK have announced promising results from their mid-stage GALAXIES Lung-201 study, which investigates the combination of Belrestotug and Dostarlimab in first-line, PD-L1 high non-small cell lung cancer patients. The study, presented at the European Society for Medical Oncology (ESMO) 2024 conference, showed a clinically meaningful objective response rate at every dose level in a follow-up interim analysis. This development has renewed cautious optimism around anti-TIGIT immunotherapy drugs, which have faced setbacks in the past. The positive response rates suggest that TIGIT could be a viable target for lung cancer treatment.
View original story
Similar markets
Yes • 50%
No • 50%
Less than 40% • 25%
40% to 50% • 25%
51% to 60% • 25%
More than 60% • 25%
Less than 40% • 25%
40% to 49% • 25%
50% to 59% • 25%
60% or more • 25%
Significant tumor shrinkage • 25%
Improved survival rates • 25%
No significant effect • 25%
Other • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Below 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Above 60% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Above 55% • 25%
50-55% • 25%
45-50% • 25%
Below 45% • 25%
Yes • 50%
No • 50%
Less than 50% • 25%
50% to 74% • 25%
75% to 80% • 25%
More than 80% • 25%